Unregistered sources of consignment raise quality questions.
Bulk drug imports are set to be the next flashpoint between India and China. The office of the Drugs Controller General of India (DCGI) has roped in, for the first time in its history, the Central Bureau of Investigation (CBI) to probe the alleged import of “unregistered” bulk drugs from China. Four cases have been handed over to CBI while three are to follow soon.
According to official sources, CBI has been asked to inquire into the import of drugs such as Roxithromycin ($81.5 per kg), Progesterone ($187.5 per kg) and Cimetidine ($14.5 per kg) by Gujarat-based Envee Drugs Pvt Ltd, and Mumbai-based firms J B Khokhani & Co and Sheetal Pharmaceuticals, respectively.
In all three cases, authorities found discrepancies in packing and labelling of the goods and the submitted documents. The Chinese manufacturers, whose names were referred to in the documents, indicated that the products were not sourced from them.
Source : Business Standard